Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,956 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Eyþórsson E, Jónsson Á, Björnsson AS, Gunnarsson GÞ, Pálsson R, Indriðason ÓS, Gíslason GK, Ólafsson A, Hákonardóttir GK, Brinkhuis M, Halldórsdóttir SL, Ásgeirsdóttir TL, Steingrímsdóttir H, Danielsen R, Dröfn Wessman I, Kampanis P, Hultcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Rögnvaldsson S, et al. Among authors: harding s. Blood Cancer J. 2021 May 17;11(5):94. doi: 10.1038/s41408-021-00480-w. Blood Cancer J. 2021. PMID: 34001889 Free PMC article. Clinical Trial.
Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
Rognvaldsson S, Eythorsson E, Thorsteinsdottir S, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Thorsteinsdóttir I, Olafsson I, Runolfsdottir HL, Helgason D, Emilsdottir AR, Agustsson AS, Bjornsson AH, Kristjansdottir G, Thordardottir AR, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Steingrimsdottir H, Kampanis P, Hultcrantz M, Durie BGM, Harding S, Landgren O, Palsson R, Love TJ, Kristinsson SY. Rognvaldsson S, et al. Among authors: harding s. Blood Cancer J. 2021 Dec 1;11(12):191. doi: 10.1038/s41408-021-00580-7. Blood Cancer J. 2021. PMID: 34853309 Free PMC article.
Redefining nonmeasurable multiple myeloma using mass spectrometry.
Giles HV, Cook MA, Drayson MT, Cook G, Wright NJ, North SJ, Harding S, Cairns DA, Hockaday A, Kaiser MF, Moss P, Davies FE, Morgan GJ, Jackson G, Pratt G. Giles HV, et al. Among authors: harding s. Blood. 2022 Feb 10;139(6):946-950. doi: 10.1182/blood.2021013794. Blood. 2022. PMID: 34871382 Free article. No abstract available.
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.
Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, Sverrisdottir IS, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Thorsteinsdottir I, Olafsson I, Thordardottir AR, Eythorsson E, Jonsson A, Gislason G, Olafsson A, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Long TE, et al. Among authors: harding s. Blood Cancer J. 2022 Sep 14;12(9):133. doi: 10.1038/s41408-022-00732-3. Blood Cancer J. 2022. PMID: 36100605 Free PMC article.
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X. Boyle EM, et al. Among authors: harding sj. Cancer. 2014 Dec 15;120(24):3952-7. doi: 10.1002/cncr.28946. Epub 2014 Aug 12. Cancer. 2014. PMID: 25116271 Free article.
Response to pneumococcal vaccination in multiple myeloma.
Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M, Cayssials E, Bories C, Herbaux C, Systchenko T, Faucompré JL, Machet A, Sabirou F, Levy A, Bobin A, Richez V, Moya N, Gruchet C, Desmier D, van de Wyngaert Z, Carpentier B, Manier S, Facon T, Harding S, Leleu X. Renaud L, et al. Among authors: harding s. Cancer Med. 2019 Jul;8(8):3822-3830. doi: 10.1002/cam4.2253. Epub 2019 May 30. Cancer Med. 2019. PMID: 31145552 Free PMC article.
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. El-Khoury H, et al. Among authors: harding s. Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25. Lancet Haematol. 2022. PMID: 35344689 Free PMC article.
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Bomsztyk J, et al. Among authors: harding s. Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399. Blood. 2024. PMID: 38194690
1,956 results